Ac-225-PSMA-617 apparently extends survival of very late-stage patients: an update

The nuclear medicine group at the University of Heidelberg in Germany recently reported a complete response in two patients treated with Ac-225-PSMA-617 (see this link). … READ MORE …

The language of denial of access to high-quality prostate cancer care today

If you look at the corporate web site for eviCore Healthcare, the company describes itself as follows: … READ MORE …